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Abstract: In the present study results related to the in vivo administration of Natural Deep Eutectic
Solvents (NADES)-solubilized berberine are reported for the first time. NADES are mixtures of
small natural compounds having a melting point significantly lower than that of any individual
component. Such solvents have gained much attention of the scientific community in the green
chemistry area, being considered useful alternatives to common organic solvents. NADES can
be used also as administration vehicles, and this can be attractive for nutraceutical products
when eutectics are formed with food grade ingredients. In this work, different NADES were
prepared using mainly food grade constituents and were tested as solvents for the alkaloid berberine.
Three selected NADES/berberine solutions and an aqueous suspension were orally administered
to mice with in dose of 50 mg/Kg. Blood levels of berberine were measured by a LC-MS/MS
method. The pharmacokinetic analysis revealed a 2–20 fold increase in blood concentration of
NADES/berberine with significant changes in pharmacokinetic profile. Natural Deep Eutectic
Solvents may thus be considered attractive solubilizing agents and may also play a role in the increase
of absorption of poorly bioavailable natural products such as berberine.
Keywords: berberine; NADES; HPLC-MS/MS; pharmacokinetic; in vivo
1. Introduction
Berberine is a quaternary benzylisoquinoline alkaloid with a very ancient use in the traditional
medicine of different countries, especially in China. This compound occurs in the root, rhizome
and stem bark of many medicinally important plant species such as Berberis spp., Coptis spp.,
Hydrastis spp. [1].
Berberine has been used orally in China since ancient times to treat diarrhea [1,2]. This alkaloid
also has a very long history of use in Ayurvedic and Chinese medicine as an antimicrobial,
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antiprotozoal, antidiarrhoic and antitrachoma agent [1–3]. In recent years, berberine has been studied
for its antihypertensive, antiarrhythmic, antihyperglycemic, anticancer, antidepressant, anxiolytic,
neuroprotective, anti-inflammatory, analgesic, hypolipidemic, nephron and hepatoprotective
properties [4–6]. Other works have evidenced the antimicrobial properties of the compound against
methicillin-resistant Staphylococcus aureus (MRSA) [6] and multidrug resistant Escherichia coli, antiviral
effects against H1NI influenza A and activity as an inhibitor of HIV protease and HIV-I reverse
transcriptase [1].
It is worth noting that this compound has also recently attracted public attention due to its
cholesterol-lowering properties. Kong et al. demonstrated the ability of the alkaloid to decrease plasma
cholesterol, via a mechanism related to the increase of LDL receptors [2]. Furthermore berberine
is also considered potentially useful for its anti-inflammatory activity and ability to decrease free
radical levels, helping the protection of the endothelial function [3,5,7]. Berberine has been studied
for its potential efficacy and safety in the treatment of type 2 diabetes mellitus patients and authors
have indicated that this alkaloid is a potent oral hypoglycemic agent with beneficial effects on lipid
metabolism [2,3,5].
Despite its therapeutic potential, pharmacokinetic studies have indicated that berberine is poorly
absorbed and that after oral administration it rapidly undergoes extensive metabolism, forming
the compounds berberrubine, thalifendine, demethylenberberine, jatrorrhizine, so that its plasma
concentration is extremely low [5,7–9]. Based on these data the oral bioavailability is considered
poor [1,4,6,8,9]. Spinozzi and colleagues [8] reported that, after a single oral dose of 500 mg of
berberine hydrochloride in human subjects, plasma levels of berberine, demethylberberine and
jatrorrhizine were lower than 0.1 nM, showing a pharmacokinetic profile with a plateau after one hour
for berberine and demethylberberine, and after 2 h for jatrorrhizine, which persisted up to 24 h. Other
authors reported that oral administration of berberine chloride resulted in very low plasma levels of
berberine, which is rapidly transferred to the liver and excreted with bile (mainly as thalifendine),
in urine (mainly as thalifendine and berberrubine) and in feces (mainly as such) [9]. In rats, after
a single oral administration of berberine (200 mg/kg) the total recovery of native compounds was
22.83%, whereas those of its metabolites were 22.74, 0.0939 and 9 × 10−6% in feces, urine and bile,
respectively [1]. In a recent review the low oral bioavailability of berberine was attributed mainly to its
poor absorption and the first-pass effect in the intestine and in the liver [9] but also to self-aggregation
of the compound in gastrointestinal fluids, to its poor permeability, P-glycoprotein (P-gp)-mediated
efflux, and hepatobiliary re-excretion [9].
In the recent years, other groups have worked in the improvement of berberine
bioavailability [9–16]. Anionic surfactants, such as sodium caprate or sodium deoxycholate have been
used as absorption enhancers. Self-emulsifying nanoparticles with sodium caprate showed a 3-fold
increase of in vitro membrane permeation and a 4-fold increase of in situ intestinal perfusion, resulting
in a 5-fold increase of in vivo bioavailability compared to pure berberine administered as powder or as
tablets. Chitosan was also studied as a berberine carrier, demonstrating absorption-enhancing activity
for its capacity to interact with the anionic components of the glycoproteins on the epithelial cell
surface, regulating tight junctions, and subsequently enhancing the drug paracellular permeability [9].
Furthermore, it was proposed that chitosan, which exerts mucoadhesive properties, can increase
drug retention at the mucosal surface, thus promoting absorption [9–16]. Other approaches used the
co-administration of compounds able to inhibit P-glycoprotein efflux such as silymarin and tetrandrine,
or a combination of D-α-tocopheryl polyethylene glycol 1000 succinate. Using a phospholipid complex
of berberine, the relative oral bioavailability in rats of berberine was 322.66% in comparison to
pure berberine, due to P-gp excretion inhibition and improvement of the liposolubility of berberine.
Other approaches have explored the use of lipidic drug delivery systems such as nano/microemulsions,
micelles, liposomes, and solid lipid nanoparticles [9].
NADES comprising natural compounds, such as organic acids, amino acids and sugars, have
been recently developed for possible application in natural product field. NADES are obtained by
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the complexation of a hydrogen acceptor and a hydrogen-bond donor. Such solvents are almost
non-volatile under ambient conditions, are chemically and thermally stable, non-flammable, and have
good solvent properties for several organic compounds [11–14]. In many cases, bioactive natural
compounds like berberine possess limited solubility in water and ethanol mixtures. This can be a
severe limitation in the extraction of bioactive compounds for food supplements and nutraceutical
ingredients [15,17]. Any alternative ideal solvent should present a high level of safety and
eco-sustainability as well as improved extraction performance [11,16,18,19]. NADES can also be
considered as ‘ingredients’ in nutraceuticals or functional foods, and offer the possibility of combining
various molecules, leading to the preparation of tailor-made solvents employable for pharmaceutical
applications [19]. Being prepared with different ingredients, NADES can be used to solubilize or
extract solutes with different properties (polarity, charge, etc.) [10–16].
During the course of our studies to evaluate NADES as absorption enhancers for poorly
bioavailable natural products [20], we considered the possibility of using this approach to increase the
bioavailability of berberine. For this purpose, several NADES were prepared and used to solubilize
berberine. Three mixtures were selected based on their solubilizing properties towards berberine,
their different chemical composition and possible issues related to the toxicity of NADES constituents.
The selected mixtures comprised basic compounds (urea) or organic acids (malic and lactic acid),
and proline. These NADES with berberine were orally administered to mice and compared to an
aqueous berberine suspension. Blood concentrations were monitored by using an ad-hoc developed
HPLC-MS/MS method. The comparison of the pharmacokinetics of the three different NADES was
used to discuss the role of eutectic solvents as absorption enhancers.
2. Results
2.1. Berberine Solubility in NADES
NADES composed of urea, amino acids, sugars and choline were used to solubilize berberine.
The prepared eutectic mixtures are listed in Table 1.
Water and ethanol were used as reference solvents due to their safety and favorable use as
solvents in the production for nutraceuticals and functional foods. Water was furthermore selected as
a reference, due to the low berberine water solubility (2.1 mg/mL at 22 ◦C). The solubility of berberine
in each solvent is reported in Table 1.
On the basis of their composition the prepared NADES have been classified into six groups: i.e.,
the first based on urea (indicated in the table with numbers 1–2), the second on an organic acid and
sugars (3), the third on organic acids and amino acids (4–14), the fourth on choline chloride (15–24),
the fifth on carnitine and acetyl carnitine (25–35), and the six on lactic acid (36–38). We selected
proline-based NADES because in our previous study [20] proline-based NADES were efficient in
solubilizing rutin. Urea-based NADES were selected because of their favorable properties in terms of
polarity and capability of creating H-bonds. Owing to the basic nature of the alkaloid berberine, we
also decided to prepare a large number of NADES based on organic acids. In particular, malic acid has
been previously studied for its ability to accumulate berberine into cells, suggesting an important role
in solubilizing the alkaloid into vacuoles [21].
Considering the results of solubility measurements, we can observe that a large number of
prepared NADES were not able to increase berberine solubility compared with water or ethanol. In fact,
ten different eutectic mixtures showed solubility higher than 2 mg/mL, and many of the prepared
solutions suffered instability (as indicated in Table 1) resulting in precipitation of the berberine.
Our results showed that choline chloride-based NADES were not efficient in the solubilization of
berberine, even though in the literature such NADES have been indicated as optimal mixtures for the
extraction of isoflavones from soy [22] and solubilization of rutin [20,23].
The best solubility result (25 mg/mL) was obtained with eutectic 14, (proline–malic acid–lactic
acid–water 1:0.2:0.3:0.5), followed by urea-based NADES (mixtures 1 and 2) with solubility higher than
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12 mg/mL. The lactic acid-based eutectics presented solubility greater than 9 mg/mL. Due to these
results and considering the possible toxicity issues deriving from their composition, the following
screening was carried out. The LD50 of urea in mice is 11,000 mg/kg, thus we selected mixture 2 instead
of 1 because it contains less urea per gram. The malic acid LD50 in rat is 1600 mg/kg, whereas those of
lactic acid in rat and mice are 3543 and 4875 mg/kg, respectively. Thus, we selected mixture 5 instead
of 6 despite the fact the solubility was 2.8 instead of 6 mg/mL.
We also observed that mixture 14, containing both lactic acid malic acids and proline with quite a
large amount of water presented the best solubility properties and can be considered an example of
tailor-made NADES targeted for berberine.
Table 1. Solubility of berberine (mean ± SD; n = 3) in NADES and reference solvents. The solubility in
all solvents were significantly different from solubility in water (p-values < 0.05).
NADES Type Composition (w/w) Berberine Solubilityat 22 ◦C (mg/mL)
Water 2.10 ± 0.05
Ethanol 2.75 ± 0.05
Urea-based
1 Proline–urea 1:1 15.0 ± 0.05
2 Proline–urea 2:1 12.3 ± 0.07 (B)
Sugar and organic acid-based 3 Citric Acid–glucose 1:1 0.54 ± 0.02
Organic acid and amino acids-based
4 Proline–Malic Acid 1:1 2.50 ± 0.06
5 Proline–Malic Acid 1:2 2.80 ± 0.05 (A)
6 Proline–Malic Acid 1:3 6.00 ± 0.09
7 Proline–Malic Acid–Water 1:2:3 1.57 ± 0.02 *
8 Proline–Malic Acid–Water 1:2:6 0.74 ± 0.01 *
9 Proline–Citric Acid 1:1 1.82 ± 0.04 *
10 Proline–Citric Acid 1:2 2.45 ± 0.03 *
11 Proline–Tartaric Acid–Citric–Acid 1:1:1 1.75 ± 0.05 *
12 Proline–Glutamic Acid 1:1 0.45 ± 0.01
13 Proline–Glutamic Acid 1:2 0.78 ± 0.02 *
14 Proline–Malic Acid–Lactic Acid–Water 1:0.2:0.3:0.5 25.0 ± 0.05 (C)
Choline chloride-based
15 Proline–Choline Chloride 1:1 1.24 ± 0.02
16 Proline–Choline Chloride 1:2 1.05 ± 0.02 *
17 Proline–Choline Chloride 2:1 0.80 ± 0.02 *
18 Choline Chloride–Malic Acid 1:1 0.30 ± 0.01 *
19 Choline Chloride–Malic Acid 1:2 1.35 ± 0.06 *
20 Choline Chloride–Malic Acid 1:3 1.56 ± 0.05 *
21 Choline Chloride–Malic Acid 2:1 1.42 ± 0.06*
22 Choline Chloride–Malic Acid 3:1 0.87 ± 0.05 *
23 Choline Chloride–Citric Acid 2:1 0.75 ± 0.02 *
24 Choline Chloride–Citric Acid 3:1 0.64 ± 0.03
25 Carnitine–Choline Chloride 1:1 0.41 ± 0.02
Carnitine-based 26 Acetylcarnitine–Choline Chloride 1:1 0.89 ± 0.05
27 Carnitine–Proline 1:1 1.07 ± 0.04 *
28 Acetylcarnitine–Proline 1:1 0.85 ± 0.03 *
29 Carnitine–Proline 1:1 1.48 ± 0.07 *
30 Carnitine–sorbitole 1:1 0.35 ± 0.01
31 Acetylcarnitine–sorbitole 1:1 0.27 ± 0.01
32 Carnitine–xylitole 1:1 0.38 ± 0.01
33 Acetylcarnitine–xylitole 1:1 0.25 ± 0.01
34 Acetylcarnitine–proline–Lactic Acid 1:1:2 1.24 ± 0.05 *
35 Acetylcarnitine–proline–Citric Acid 1:1:2 1.36 ± 0.04 *
36 Lactic Acid 9.00 ± 0.05
Lactic Acid-based 37 Lactic Acid–Water–Citric Acid 1:1:0.1 10.00 ± 0.06
38 Lactic Acid–Water–Ossalic Acid 1:1:0.1 10.00 ± 0.09
* An asterisk indicates instability of the prepared berberine in NADES solution, evidenced by precipitation or
crystallization of constituents.
Thus, based on this preliminary evaluation, in order to explore the behavior of these NADES as
in vivo absorption enhancers, we selected mixture 5 (henceforth indicated as “A”) and 2 (indicated as
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“B”) as examples of urea and malic acid-based NADES; then mixture 14 (indicated as “C”) as the best
solubilizing eutectic for the pharmacokinetic evaluation.
2.2. HPLC-MS/MS Method Validation
2.2.1. Specificity, Linearity, LOQ and LOD
Exemplificative multiple reaction monitoring (MRM) chromatograms for berberine-spiked plasma
(berberine 45 ng/mL, benzanilide (the internal standard or ISTD, 100 ng/mL) are reported in
Figure 1. Selected transitions for quantification were 336 → 291 for berberine and 198 → 105 for
the ISTD benzanilide.
Five calibration mixtures prepared mixing different ratios of berberine/ISTD (namely, 0.008654,
0.0108, 0.04326, 0.0649, and 0.108) were used to build a calibration curve (y = area of berberine/area
of ISTD; x = quantity of berberine/quantity of ISTD) that was linear and reliable over the considered
calibration range. The retention times of berberine (5.7 min) and ISTD (8.0 min) and specific MS/MS
transitions allowed the identification of compounds. Limits of quantification (LOQ) and detection
(LOD) for berberine were 0.3 ng/mL and 0.9 ng/mL, respectively.
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Figure 1. HPLC-MS/MS chromatogram of plasma spiked with ISTD and berberine and blank plasma.
2.2.2. Accuracy and Precision
Spiked samples were assayed for intra-day and inter-day precision and accuracy at concentrations
of 0.9, 4.5, 9, 22.5 ng/mL of berberine. Data are summarized in Table 2.
Table 2. Intra-day and inter-day precision and accuracy at different concentrations.
Nominal Concentration ng/mL Measured ng/mL RSD (%) Accuracy (%)
Intra day (n = 5) 0.9 0.947 ± .081 1.6 105.2
4.5 4.61 ± 0.34 6.8 102.4
9 8.92 ± 0.13 2.6 99.1
22.5 23.2 ± 0.68 13.7 103.2
Inter day (n = 5) 0.9 0.934 ± 0.088 1.9 103.7
4.5 4.56 ± 0.24 7.0 101.3
9 8.93 ± 0.17 3.8 99.2
22.5 23.0 ± 0.51 11.0 102.2
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2.3. Pharmacokinetics of Selected Eutectic Solubilised Berberin and Berberine Hydrochloride Water Suspensions
in Mice
Eutectics formed with A, B and C were selected to evaluate their pharmacokinetic properties in
mice and were compared with berberine hydrochloride water suspension. Plasma levels of berberine
were determined up to 6 h after its oral administration (50 mg/kg) by gavage in mice. As reported in
Table 3 and Figure 2, different plasma levels were observed. For water and the three eutectic mixtures,
the maximum peak was observed after 30 min.
Table 3. Mean (mean ± DVST, n = 3) measured plasmatic concentrations of berberine after oral
administration (50 mg/kg) in mice. Used eutectics are indicated with letters, namely, A: Proline Malic
Acid 2:1, B: Proline Urea 2:1, C: Lactic Acid: Proline: Malic Acid: Water.
Time (Min)
Water A B C
ng/mL ng/mL ng/mL ng/mL
10 3.83 ± 0.51 4.75 ± 0.49 11.33 ± 1.10 21.80 ± 2.88
30 6.40 ± 0.32 20.71 ± 3.63 46.94 ± 6.00 51.21 ± 9.20
60 4.66 ± 0.36 4.73 ± 1.81 10.36 ± 2.00 32.23 ± 8.50
180 8.50 ± 1.70 1.10 ± 0.09 7.60 ± 0.90 22.72 ± 5.00
360 4.68 ± 0.37 0.74 ± 3.00 4.50 ± 0.50 14.62 ± 6.91
The observed plasma levels of berberine administered with the three eutectic mixtures were
significantly higher than that occurring in water suspension (p < 0.05) after 30 min. For B and C
the values at 10, 60 and 180 min were also significantly different (p < 0.05) compared with the water
suspension. The increase of the plasmatic peak at 30 min was 3.2, 7.3 and 8.0 times higher for NADES
A, B and C, respectively. Table 4 summarize the non-compartmental pharmacokinetic parameters
of berberine following oral administration of the same dose of berberine suspended in water or
solubilized in the three considered NADES in Balb/c mice.
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Figure 2. Time course (mean ± SD) of plasma concentration of berberine in Balb/c mice following oral
administration of 50 mg/kg in NADES solution or suspension in water.
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Table 4. Non-compartmental pharmacokinetic parameters of berberine following oral administration
in Balb/c mice.
Suspension A B C
tmax (min) 180 30 30 30
Cmax (ng/mL) 8.5 20.8 46.9 51.2
t1/2 λz (min) 208 268 248 265
AUClast (ng min/mL) 2226 1170 3499 8640
AUC (ng min/mL) 3630 1904 5112 14,219
AUC (%Extrapolated) 39 39 31 39
MRT (min) 371 354 315 384
Fr (%) 100 52 141 392
3. Discussion
Natural deep eutectic solvents can be attractive options in nutraceutical formulations and
for pharmaceutical applications [15,20,24,25]. In this paper, we showed that the preparation of
some NADES using mainly food grade materials, namely the eutectics A (proline–malic acid 2:1),
B (proline–urea 2:1) and C (lactic acid–proline–malic acid–water) solubilized berberine better than
reference solvents (water and ethanol). In particular, for the mixture C, we can explain the good
performance in terms of solubility. The eutectic C contains two acids, namely malic and lactic.
We selected this mixture due to the fact that malic acid was reported to form soluble berberine
malate [21]. The eutectics 36–38 of the present work, containing lactic acid, were able to solubilize
berberine at values of 10 mg/mL. Furthermore, the presence of a small amount of water strongly
increased the solubility of berberine in the mixture C compared with the eutectics 7 and 8 (higher
amounts of water) or 4–6 (without water). Our results on eutectic C are in agreement with previously
published data indicating that the properties of NADES can be modulated by water due to changes in
hydrogen-bonding interactions that are weakened by water dilution. The same authors also indicated
that the solubility of compounds in NADES can be adjusted by changing the water content [14].
The three selected effective eutectics possess proline in their composition. On the other hand,
several other tested mixtures (i.e., 3–13) containing proline were not efficient in solubilizing berberine.
A further consideration is related to the presence of basic compounds such as urea, in efficiently
solubilizing NADES. Also, acidic compound-based eutectics such as the lactic acid-based ones
36–38 showed good solubilization properties. The collected data show the opportunity to create
specific eutectic mixtures in order to solubilize specific compounds. On the basis of the prepared
eutectics we can postulate a tailor-made NADES for the berberine solubilization requires the presence
of an organic acid (lactic or malic), amino acids and water. The presence of these components strongly
influences the solubility properties. As a matter of fact, eutectic mixtures containing only proline
and malic acid (4–5) showed better solubilization properties compared with the corresponding ones
containing water (7 and 8), but mixture 14, containing 1:0.2:0.3:0.5 proline–malic acid–lactic acid–water,
showed improved properties. Thus, small amounts of water are needed to increase the berberine
solubilization in organic-acid-proline-based eutectics. The overall results showed a moderate ability
(5- to 10-fold) of NADES to solubilize berberine with urea, lactic acid and water-containing NADES.
Considering the pharmacokinetic analysis, the administration by gavage to mice resulted in
different behavior comparing water suspension and NADES. An increase of bioavailability of berberine,
especially for the eutectic C, was observed as indicated in Table 2, being the AUC four times the
one observed with water suspension. The administration of NADES with dissolved berberine
yielded in a significant increase of the plasma alkaloid peak at 30 min. All the prepared NADES
showed similar pharmacokinetic profiles in the explored range of times, with no differences in the
observed tmax between the urea-based and the acidic compound-based eutectics, suggesting that the
increase of bioavailability observed is mainly related to the solubilization properties of the different
eutectic mixtures.
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4. Materials and Methods
4.1. Chemicals
Sugars and polyols were obtained from Carlo Erba (Milan, Italy). Citric and oxalic acids were
purchased from Riedel-De-Haen AG (Seelze, Germany), tartaric acid from Codex (Turin, Italy),
malic acid from Carlo Erba, proline from Fagron (Bologna, Italy). Choline chloride was purchased
from Sigma-Aldrich (Milan, Italy) and urea from Alfa Aesar (Karlsruhe, Germany). Glutamic acid,
acetylcarnitine and carnitine were purchased from ACEF s.p.a. (Fiorenzuola D’Arda, Italy). Berberine
and the internal standard benzanilide were purchased from Sigma-Aldrich. Solvents such as HPLC
grade acetonitrile and methanol were purchased from Scharlau (Barcelona, Spain), and formic acid
from Carlo Erba.
4.2. NADES Preparation
NADES have been prepared using mixtures of sugars (glucose, xylitol, sorbitol), amino
acids (glutamic acid, proline), organic acids (citric, malic, oxalic and tartaric acid), and other
nitrogen-containing compounds (urea, choline chloride, acetylcarnitine and carnitine). For NADES
preparation the approaches described in the review of Dai et al. [11] were applied.
4.3. Solubility Trials and Quantification of Solubilized Berberine in the NADES by HPLC-DAD
A precisely weighed amount of berberine was suspended in water, ethanol and in the various
prepared NADES with an initial concentration of 2.5 mg/mL, then increased according to the solubility
capacity of the different solvents (25 mg/mL was the highest concentration reached). Samples were
placed on a magnetic stirrer (Stuart, Bibby Scientific Ltd., Stone, Staffordshire, UK) at 22 ◦C for 1 h,
then centrifuged for 21 min at 13,000 rpm with a 5415 R centrifuge (Eppendorf, Hamburg, Germany).
For quantitative measurement of solubilized berberine, a portion (100 µL) of the clear supernatant
obtained after centrifugation was diluted 1:5 (v/v) in ethanol.
For quantification, stock standard solution of berberine (100 µg/mL) was prepared dissolving
the analytical standard in methanol using an ultrasonic bath. A calibration curve was obtained
injecting standard solutions of berberine at different concentrations, namely 50, 25, 10, 5 and 1 µg/mL.
The following calibration curve was obtained: y = 18,323–50,294 (R2 = 0.9997). The Limit of
Quantification (LOQ) was 1 µg/mL.
For HPLC-DAD analysis, an Agilent series 1260 HPLC instrument (Agilent, Cernusco Sul
Naviglio, MI, Italy) equipped with a quaternary pump, a diode-array detector, an auto sampler
and a column oven compartment was used. Analyses were performed on Eclipse XDB C8 column
(5 µm, 4.6 mm × 150 mm, Agilent). The mobile phase was (A) water–formic acid (99:1 v/v) and (B)
acetonitrile. A gradient program was used as follows: 0 → 11th min: A:B (90:10) → A:B (0:100)
11→ 12th min: A:B (0:100)→ A:B (0:100) 12→ 12, 10th min: A:B (0:100)→ A:B (90:10) 12, 10→ 14th
min: A:B (90:10)→ A:B (90:10). The mobile phase flow rate was 1 mL/min and the injection volume
was 10 µL. The chromatogram was recorded at 350 nm and spectral data for all peaks were obtained in
the range of 190–400 nm. The retention time of berberine under these analysis conditions was 6.16 min.
4.4. Animals Blood Collection and Extraction
All experimental protocols involving animals were reviewed and approved by the Ethical
Committee for animal Experiments of the University of Padua (CEASA; 49,571). Female, Balb/c mice
(8–10 weeks old) were housed (three per cage) in polycarbonate cages and kept on a 12 h light/dark
cycle. Food and water were given ad libitum. Mice, randomly divided into groups of 15 animals, one
group (n = 15) for each NADES and berberine suspended in water. Each group received 50 mg/kg
of berberine by oral gavage as water suspension (group 1) or solubilized in the selected NADES
(group 2). A single blood sample was collected by cardiac puncture from each animal at 10, 30, 60,
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180, and 360 min after dosing (three animals were used for each time point). The whole blood was
heparinized, then three samples were obtained for each time point and each treatment group.
4.5. HPLC-MS Plasma Analysis
Standard stock solutions for determination of berberine in mice blood were prepared by dissolving
berberine and the ISTD benzanilide in methanol. The calibration curve was obtained mixing 500 µL of
0.8 µg/mL ISTD with different volumes (500, 300, 100, 50, and 25) of 90 ng/mL berberine standard
solution in order to obtain different berberine/benzanilide quantity ratios. Mixture of ISTD and
berberine were added to blank plasma samples and used for sample and calibration curve preparation.
500 µL of IS solution were added to 400 µL of whole blood (461 ng) in order to precipitate proteins.
Three mL of water were added, followed by 7 mL of ethyl acetate. Samples are mixed in a vortexer
and subjected to 5 min ultrasound in a bath at room temperature. The sample was then centrifuged
and the clear supernatant was concentrated under vacuum at 50 ◦C. 200 µL of methanol were then
used to dissolve the residue and used for HPLC-MS/MS measurements.
For analytical measurements, an Agilent series 1260 HPLC chromatograph equipped with a Varian
Prostar 410 autosampler and coupled with a Varian 320 TQD MS spectrometer was used. The mass
spectrometer was equipped with electrospray ionization (ESI) source as the interface and analysis was
conducted in negative ion mode for both the analytes. Analyses were performed on a Polaris 3 C18-A
150 × 3.0 mm (Agilent Technologies). The mobile phase was (A) water–formic acid (100:1.0 v/v) and
(B) acetonitrile. A gradient program was used as follows: [0→ 1th min: A:B (70:30) isocratic, 1→ 7th
min: A:B (70:30)→ A:B (15:85) 7→ 15th min: A:B (15:85)→ A:B (15:85), and re-equilibrating time A:B
(70:30) for 5 min. The mobile phase flow rate was 0.3 µL/min. The injection volume was 5 µL.
The ESI source was set in positive ionization mode. Quantification was performed using multiple
reaction monitoring (MRM) with m/z 336 > 291 transition for berberine and m/z 198 > 105 transition
for the ISTD. The MS parameters were capillary voltage 60 V, needle voltage 4200 V, shield voltage
600 V, collision energy 22 V, Q1 voltage 0.7 V and Q3 voltage 2.8 V, nebulizing gas pressure 50 psi
and drying gas pressure 25 psi. Calibration curve using the ratio peak area berberine/peak area ISTD
versus quantity berberine/quantity ISTD was y = 0.9701x + 0.0028, R2 = 0.9899. The limit of detection
(LOD) was 0.3 ng/mL and the limit of quantification was 0.9 ng/mL.
4.6. Method Validation
Assay specificity was evaluated comparing the chromatograms of standard-spiked plasma
with blank plasma from three different sources. Calibration curves were fitted by least square
regression analysis to plot peak area ratio of berberine/ISTD relatively to the ratio of the amount of
berberine/ISTD. Limit of Quantification (LOQ) was calculated as the lowest amount with a relative
standard deviation <20%. Intra- and inter-day stability, extraction recovery, were measured. Precision
and accuracy were evaluated using QC samples (n = 5) at concentrations of 0.9, 9, 22.5 and 45 ng/mL
on two different days. Different plasma samples were used for intra- and inter-day stability, extraction
recovery, with five replicates.
4.7. Pharmacokinetic Analysis
Non-compartmental pharmacokinetic analysis was performed using WinNonlin Version 2.1
(Pharsight Corporation, Mountain View, CA, USA) software. The area under the mean plasma
concentration-time curve extrapolated to infinity (AUC) was calculated using a linear-up and log-down
method. Maximum concentration and the time when it was observed (Cmax and tmax, respectively)
were reported as observed. Terminal half-life (t1/2) was calculated as t1/2 = ln2/λz, where λz is the
slope of the terminal phase of the plasma concentration-time curve in the semi-log plot calculated
by linear regression. Mean residence time (MRT) was calculated as AUC/AUMC, where AUMC
is the area under the first moment curve. Relative bioavailability Fr of NADES versus suspension
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was estimated as a ratio of AUC following the administration of NADES and AUC following the
administration of the suspension.
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